Johnson & Johnson (NYSE:JNJ) on Wednesday reported a fourth-quarter 2025 adjusted earnings of $2.46 per share, up 20.6% year over year, beating the consensus of $2.44.
The pharmaceutical and medtech giant reported sales of $24.56 billion, up 9.1% year over year and beating the consensus of $24.16 billion.
Operational growth was 7.1%, and adjusted operational growth was 6.1%.
Innovative Medicine sales increased 10% or 7.9% operationally to $15.76 billion. Fiscal 2025 sales increased 6% to $60.40 billion.
2025 operational sales grew 5.3%, with net acquisitions and divestitures positively impacting growth by 1.2% primarily due to Caplyta.
Growth was driven primarily by Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Erleada (apalutamide), and Rybrevant/Lazcluze in oncology, Tremfya (guselkumab) and Simponi/Simponi Aria in immunology, and Spravato (esketamine) in neuroscience.
Growth was partially offset by an approximate (1,040) basis points impact from Stelara in Immunology.
Cancer drug sales increased to $6.86 billion, up 24.8% (+21.9% operational). Immunology sales declined to $3.86 billion, a 8.9% decrease (or 10.3% on an operational basis).
MedTech sales increased 7.5% to $8.80 billion. 2025 operational sales grew 5.4%, with net acquisitions and divestitures positively impacting growth by 1.1% primarily due to Shockwave.
Growth was driven primarily by electrophysiology products and Abiomed in Cardiovascular, and wound closure products in General Surgery.
Johnson & Johnson, in its earnings presentation, highlighted that its cancer cell therapy Carvykti and Shockwave each generated annual sales of over $1 billion.
The company said it has 28 platforms with at least $1 billion in annual revenues.
Outlook
Johnson & Johnson issued fiscal 2026 adjusted earnings guidance of $11.43-$11.63, compared to the consensus of $11.45.
The company expects 2026 sales of $99.50 billion-$100.5 billion compared to the consensus of $98.89 billion.
Price Action: Johnson & Johnson shares were down 0.90% at $216.24 during premarket trading on Wednesday. The stock is trading near its 52-week high of $220.11, according to Benzinga Pro data.
Photo by Tada Images via Shutterstock
